Wells Fargo & Company MN raised its position in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 20.3% in the second quarter, HoldingsChannel reports. The fund owned 167,344 shares of the company’s stock after acquiring an additional 28,203 shares during the period. Wells Fargo & Company MN’s holdings in Global Blood Therapeutics were worth $8,802,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. Taylor Wealth Management Partners raised its position in shares of Global Blood Therapeutics by 0.5% in the second quarter. Taylor Wealth Management Partners now owns 44,801 shares of the company’s stock valued at $2,357,000 after buying an additional 217 shares in the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of Global Blood Therapeutics by 1.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 25,279 shares of the company’s stock valued at $1,338,000 after buying an additional 310 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Global Blood Therapeutics by 17.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,265 shares of the company’s stock valued at $172,000 after buying an additional 482 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in shares of Global Blood Therapeutics in the second quarter valued at approximately $27,000. Finally, Metropolitan Life Insurance Co NY raised its position in shares of Global Blood Therapeutics by 3.4% in the first quarter. Metropolitan Life Insurance Co NY now owns 16,873 shares of the company’s stock valued at $893,000 after buying an additional 562 shares in the last quarter. Institutional investors own 97.99% of the company’s stock.

A number of research firms have recently weighed in on GBT. Cowen set a $83.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Thursday, September 5th. Cantor Fitzgerald set a $110.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Friday, June 14th. HC Wainwright set a $150.00 price target on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Friday, September 6th. Morgan Stanley set a $60.00 price target on shares of Global Blood Therapeutics and gave the company a “hold” rating in a research report on Friday, August 9th. Finally, BidaskClub upgraded shares of Global Blood Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 6th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $89.75.

GBT traded down $0.12 during trading on Friday, hitting $54.19. 107,582 shares of the stock traded hands, compared to its average volume of 883,383. Global Blood Therapeutics Inc has a twelve month low of $30.15 and a twelve month high of $64.94. The company has a market cap of $3.25 billion, a price-to-earnings ratio of -15.89 and a beta of 1.58. The company has a debt-to-equity ratio of 0.03, a current ratio of 16.79 and a quick ratio of 16.79. The business has a 50 day moving average price of $49.97 and a 200 day moving average price of $54.43.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.05). During the same quarter last year, the business posted ($0.78) EPS. On average, equities research analysts predict that Global Blood Therapeutics Inc will post -3.98 earnings per share for the current year.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

See Also: Swap

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.